AI Terminal
GRAFT POLYMER (UK) PLC
Regulatory Filings • Feb 25, 2025
5092_rns_2025-02-25_1eac8070-07d3-4d2d-9b97-ffa03d18b0b8.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2530Y
Solvonis Therapeutics PLC
25 February 2025
RNS Reach - non-regulatory announcement
25 February 2025
Solvonis Therapeutics plc
("Solvonis Therapeutics" or the "Company")
Solvonis Therapeutics - Advancing Treatments for Mental Health and Addiction
Solvonis Therapeutics (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces that Anthony Tennyson, Chief Executive Officer of the Company, will be presenting Solvonis Therapeutics plc in the Strategy and Growth track at the PharmaSynergyRx 2025 event in London on 27 February 2025.
PharmaSynergyRx brings together over 200 Business Development and C-suite executives, creating a platform for companies pursuing co-developments, partnerships, licensing and commercial deals within the bio-technology industry.
For more information, please visit: https://pharma-synergy-conference.com/pharmasynergy-2025/
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: [email protected]
Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Solvonis Therapeutics plc
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.
www.solvonis.com | LinkedIn | X (formerly Twitter)
About Reach announcements
This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRADZGZZKDKGKZM